Introduction {#s1}
============

Prostate cancer is one of the most common malignancies and the second leading cause of cancer death among men in the United States [@pone.0002079-Jemal1]. The molecular mechanisms of prostate cancer development and progression remain poorly understood. Genetic and epigenetic alterations contribute to prostate cancer formation, as with most other cancers. DNA hypermethylation is the most common epigenetic abnormality in cancer. Hypermethylation of CpG islands in promoter regions usually results in gene silencing, and several tumor suppressor genes are hypermethylated in their promoter regions in human cancers, which is thought to contribute to tumorigenesis [@pone.0002079-Herman1], [@pone.0002079-Baylin1]. Therefore, DNA hypermethylation may serve as a useful target to clone novel tumor suppressor genes. In prostate cancers, inactivation by aberrant methylation has been reported for many genes, such as APC [@pone.0002079-Kang1], HIC1 [@pone.0002079-Yamanaka1], RARβ2 [@pone.0002079-Nakayama1], GSTP1 [@pone.0002079-Singal1], CDH1 [@pone.0002079-Graff1], MDR1 [@pone.0002079-Yegnasubramanian1] and RASSF1A [@pone.0002079-Liu1].

Although the list of aberrantly methylated genes is expanding, only a few genes show promise as tumor biomarkers for early diagnosis and risk assessment of prostate cancer. Thus, large-(genome wide) scale screening of aberrant methylation of CpG islands is needed to identify prostate-specific epigenetic markers. To identify CpG islands differentially methylated in prostate cancer and other cancers, we performed methylated CpG island amplification (MCA) coupled with representational difference analysis (RDA) [@pone.0002079-Toyota1]. Applying this method to prostate cancer, we isolated 34 clones that corresponded to promoter CpG islands. Several are promising biomarkers for prostate and other cancers.

Materials and Methods {#s2}
=====================

Cell lines and tissue samples {#s2a}
-----------------------------

Cell lines used in this study were obtained from the American Type Culture Collection (Manassas, VA). All cell lines were cultured in recommended medium in the presence of 10% FBS in a humidified atmosphere containing 5% CO~2~ at 37°C. Samples of colon cancer paired with normal colon mucosa and samples of breast cancer paired with normal breast were obtained from established tissue banks at the University of Texas M. D. Anderson Cancer Center (Houston, TX). Samples of prostate cancer and normal prostate were obtained from Baylor College of Medicine (Houston, TX). Microdissection was employed to isolate prostate cancer cells and non-neoplastic prostate epithelial cells. SVHUC, normal urothelial cells, immortalized in vitro by SV40 was a gift from Dr. Bogdan Czerniak (M. D. Anderson Cancer Center). DNA was isolated by extraction buffer with 100 µg/ml proteinase K (Sigma, St. Louis, MO) and standard phenol-chloroform methods. All samples were collected from consenting patients according to institutional guidelines.

MCA/RDA {#s2b}
-------

MCA/RDA was performed as described [@pone.0002079-Toyota1]. Briefly, 5 µg of DNA was digested with *Sma*I followed by *Xma*I (New England Biolabs, MA). The restriction fragments were ligated to adapters and amplified by PCR. The reaction mixture was incubated at 72°C for 5 min and at 95°C for 3 min, and then was subjected to 25 cycles of 1 min at 95°C and 3 min at 77°C followed by a final extension of 10 min at 77°C. MCA amplicons from the prostate cancer cell lines DU145, PC3 and LNCaP were mixed and used as the tester for RDA. MCA amplicons were generated from a mixture of normal blood and normal colon mucosa DNA was used as the driver. Two rounds of RDA subtractive hybridization were performed on these MCA amplicons using different adapters, JMCA and NMCA. After the third round of subtractive hybridization and selective amplification, the RDA products were cloned into a TOPO TA cloning vector (Invitrogen, Carlsbad, CA). Sequence analysis was carried out with an ABI PRISM 377 DNA sequencer (Applied Biosystems, Foster City, CA) at the DNA sequencing core facility at the University of Texas M. D. Anderson Cancer Center.

DNA bisulfite treatment {#s2c}
-----------------------

After DNA extraction, DNA was treated with bisulfite as reported previously [@pone.0002079-Clark1]. Two µg of genomic DNA were denatured by 0.2 M NaOH at 37°C for 10 minutes, followed by incubation with freshly prepared 30 µl 10 mM hydroquinone (Sigma) and 520 µl 3 M sodium bisulfite (pH 5.0) at 50°C for 16 hours. Bisulfite-converted DNA was purified with a Wizard miniprep Column (Promega) and incubated with 0.3 M NaOH for 5 minutes at room temperature. DNA was then precipitated with ammonium acetate and ethanol, washed with 70% ethanol, dried and dissolved in 40 µl distilled water. We used *Sss*I methylase (New England Biolabs) - treated normal leukocytes DNA as a positive control for methylation studies.

Combined bisulfite restriction analysis (COBRA) and Pyrosequencing {#s2d}
------------------------------------------------------------------

We used bisulfite-PCR followed by COBRA [@pone.0002079-Cottrell1] and/or Pyrosequencing [@pone.0002079-Colella1] to analyze the methylation status of cell lines and patient samples. PCR reactions were carried in 50 µl reaction volume; including 2 µl bisulfite treated DNA, 2 mM MgCl~2~, 0.25 mM dNTP, 1 unit *Taq* polymerase, 16 mM (NH~4~)~2~SO~4~, 67 mM Tris-HCl (pH 8.8), 1 mM 2-mercaptoethanol and 100 nM primers. COBRA primers and restriction enzymes for digestion are shown in [Table 1](#pone-0002079-t001){ref-type="table"}. PCR products after restriction enzyme digestion were separated in 5% nondenaturing polyacrylamide gels, followed by densitometric analysis to obtain quantitative methylation levels. Densitometric analysis was performed using a BioRad Geldoc 2000 digital analyzer equipped with the Quantity One version 4.0.3 software (BioRad, Hercules, CA). SLC16A12, TOX, GALR2, TFAP2C and PAX9 were analyzed by COBRA and/or quantitated using the PSQ HS 96 Pyrosequencing System (Pyrosequencing Inc, Westborough, MA) [@pone.0002079-Colella1]. In order to determine the quantitative accuracy of the COBRA and pyrosequencing assays, we tested DNA from normal leukocytes spiked with 0%, 33%, 67% and 100% methylated DNA obtained by *Sss*I methylase treatment.

10.1371/journal.pone.0002079.t001

###### Primers used in this study.

![](pone.0002079.t001){#pone-0002079-t001-1}

  COBRA                                                                         
  ---------- ---------------------------- ---------------------------- -------- -------------
  NSE1          GAATTAAGGTTTTGGGGGATT         CCCAAAACACCCCAATATAA      109 bp   *HpyCH*4IV
  TFAP2C        GGGGTGGGTTTTAGTATTTGG         CCAACCAATCCCAACCTAAC      224 bp     *Hpa*I
  TFAP2E          GGGTTTATGGAGGTAGGA       AAAAACTACCATAACTTATCTCTTTA   179 bp     *Hpa*I
  CDEP            TTTTGTTTGGGGTTGTTT          ACTCCCCCAAACTTAAATC       142 bp    *Hpy188*I
  NKX2-5        GAGAGTAGGGTTGGGGAATATG      AACCCCTAACCCAATAACAAACT     236 bp     *Bst*UI
  BTBD14A        GGGAGAGTTTTYGGGTTTTT       AAACCCAATCCAAACAACTTACA     238 bp     *Rsa*I
  IRX5        GAGTAATTTTTGAGTTTAAGGTTTGG     AACAACCAAAAACCAAATACCC     527 bp   *HpyCH4*III
  ETNK2       GAAGGGGGTATAGTTATTTTTAGTAG    TAAATCATAAACTTCCCCTAACC     126 bp     *Hinf*I
  GALR2         GGTTAGGAGGAGGAGTAAGAGA       CTACACCCCTACCAAACTACAA     313 bp   *HpyCH*4IV
  DPYS         TAGAATATTTGGGGTTTGAGTGT      TTAAAATACCCTCCTACAAAATCC    200 bp     *Hinf*I
  CLSTN1       AAATTGGGAGGATTTTAAGATTT        CCCAAAACCCTTATCACTTC      385 bp   *HpyCH*4IV
  SPOCK2      GGGGTTTTGATTTTTGTAGTATTTT    TTTCAAACAAATACATCTCCTAACC    165 bp     *Rsa*I
  EGFR5       GAGTTGTTTTTAATTTGGATTTGTT     CAACTATATTCCTAACCCCAAAA     121 bp   *HpyCH*4IV
  FOXN4         GGGTTTTTATTTTGGAAATGTA      CCCTACCCTATAACTAACCCTTA     291 bp     *Bst*BI
  TOX1         GTGGTTTGTTTAAGAAGAAGAGGA     ACAAAACAACTCAAAATCTCCAAT    289 bp     *Taq*I
  SLC16A12        GGGGTATGGGGGTGGTTT         ACCCAACCCAAACAAAACAAAT     397 bp    *Hpy188*I
  PAX9          GGAAAGTTTTTGTTTGGGAGTG      AATAACATCAACAACCACCCAAT     284 bp     *Hinf*I

  Pyro-sequencinig                                                                        
  ------------------ ------------------------------- ------------------------------------ ----------------------------
  PAX9                 TTTAGGTGGGGAGTTAGTTTGAAAGA     U-ACCAATCCCAAAACAAACTACATAATAATTAA       AAGGAGTTTTTTGGATTG
  SLC16A12              TAGAGGGAGAGGTGGTTTAGGTGAT         U-CACCCAAATTAAAATCCCAAACTC          AAGGGTATTTTTTAAGGAAG
  TOX                 GGGGATAATGAGAGTATGAAGTTATTTGT     U-CCCTCACATCCCTTTATAATTTATTTAA         GGAGGAGGTGGAGTAGG
  DPYS                   TTAGTTTTTTAGGGGGGAGGAGT           U-ACCCCCCAACTCTACCTCAAAC        GTAGTATATGAGGTTAGGTTATAAAT
  NKX2-5                 AGAGTAGGGTTGGGGAATATGG           U-CCCTCTCCTACCCCTTATACTCAA            TAGGTGGGAGGTAGAA
  SPOCK2                TAGAGGGAGGAGAGTTGAGGATAG      U-TCCACCTAAAAAAATCTTAACTTCTACAATA       GGAGGAGAGTTGAGGATAG
  EGFR5                 GGTTGGGGAAGTTAGTTGTAGAGG         U-ACCCAAAACTACTCCCAACTTAAATC         GGGAAGTTAGTTGTAGAGG
  GALR2                 GGGGTTAGGAGGAGGAGTAAGAGA            U-ACCACTCCCCAACCCTTCC             GGAGAGGTTGTTTTTAGTAG
  TFAP2C               GGTTTTAGGGGAGGAGTTATGATAAT          U-CCCCCCAACAATATATCCTAA         TTATGATAATTTTTTTTTTATTAAG

  RT-PCR                                                      
  -------- ------------------------- ------------------------ --------
  GALR2      GCACTTCCTCATCTTCCTCA      GACTGGCGGTAGTAGCTCAG    198 bp
  DPYS       CTGTACGAAGCCTTCTCTCG      CCTTAGCTGCAGACTTGCTC    247 bp
  TPAP2C     CCCACTGAGGTCTTCTGCTC      AGAGTCACATGAGCGGCTTT    245 bp
  NSE1      CAGGAGACTTTAAAGGAGTTTGG   TCATCATCCGAGAAGAAGTAGG   206 bp
  TFAP2E      GACCTGCAGGCAATGGAC      CCTTGTACTTGGACGTTGAGC    205 bp
  CDEP      GGTACGATGATCAAGATGGAGA    CGTGGACTTTAAACTGATTGGA   223 bp
  NKX2-5     CCCTAGAGCCGAAAAGAAAGA    GGTTCTGGAACCAGATCTTGAC   251 bp
  SPOCK2    GAGACGAAGTGGAGGATGACTA    CTTGCAGATGGAGTCTTTGTTT   227 bp
  GAPDH      ACAGTCAGCCGCATCTTCTT      GACAAGCTTCCCGTTCTCAG    259 bp

Y = C or T.

U = biotin labeled universal primer tag : 5′-biotin-GGGACACCGCTGATCGTTTA.

RNA purification and reverse transcription-PCR (RT-PCR) {#s2e}
-------------------------------------------------------

Gene expression was analyzed by RT-PCR. Total RNA obtained from different cell lines was isolated using the TRIZOL reagent (Molecular Research Center, Inc., Cincinnati, OH). Reverse transcription reactions were performed using MMLV-RT (Takara) and random hexamers on 5 µg of total RNA per reaction according to the manufacturer\'s protocol and amplified by PCR using primers shown in [Table 1](#pone-0002079-t001){ref-type="table"}. GAPDH mRNA was used as an internal control.

Treatment with *5-Aza-2′-deoxycytidine (5-AzadC)* and/or *Trichostatin A (TSA)* {#s2f}
-------------------------------------------------------------------------------

Cancer cells were split 12--24 h before drug treatment. Cancer cells were treated with 5-AzadC (Sigma) and TSA (ICN, Irvine, CA) either alone or in combination. Cells were exposed continuously to 5-AzadC (1 µmol/L refreshed daily) for 3 days or to TSA (300 nmol/L) for 20 hours. For combined treatment, cells were cultured in the presence of 5-AzadC (1 µmol/L refreshed daily) for 3 days and exposed on the third day (24 hours) in combination with TSA (300 nmol/L). Mock-treated cells were cultured similarly.

Statistical Analysis {#s2g}
--------------------

Statistical analyses were performed using Prism 4 software (GraphPad Software, Inc., San Diego, CA). The Pearson test was used to determine correlations. The Fisher\'s exact test and t-tests were used to compare methylation in normal and cancer tissues. We used a cut-off corresponding to average methylation in normal tissues+2 standard deviation (*s~D~*) to call a cancer as methylation positive (above the cut-off). Sensitivity, specificity and accuracy of each individual or 2 combined candidate biomarkers were calculated. Sensitivity was defined as the number of true-positive (methylated in cancer) cases divided by the number of true-positive plus false-negative (not methylated in cancer) cases and specificity was defined as the number of true-negative (not methylated in normal tissue) cases divided by the number of true-negative plus false-positive (methylated in normal tissue) cases. The accuracy of a test is measured by the area under the Receiver Operating Characateristic (ROC) curve. All reported p values were 2-sided and *P*\<0.05 was considered statistically significant.

Results {#s3}
=======

Detection of Methylated CpG Islands Using MCA-RDA {#s3a}
-------------------------------------------------

To identify novel CpG islands aberrantly methylated in prostate cancer, we used MCA-RDA [@pone.0002079-Toyota1]. RDA was performed on MCA amplicons from a mixture of the prostate cancer cell lines DU145, PC3 and LNCaP as a tester, and a mixture of normal colon mucosa DNA from three different men and normal leukocytes from two different men as a driver. After 2 rounds of RDA, PCR products were cloned and DNA sequencing was performed on 198 randomly selected clones. Of the 198 clones, 17 corresponded to repeats including *Alu*, 94 corresponded to non-CpG island DNA, 50 corresponded to non-promoter CpG islands and 37 corresponded to 34 unique promoter associated CpG islands, as revealed by BLAST ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)) and BLAT (genome.ucsc.edu) searches. The homology of each unique promoter associated clone, chromosomal location, and GenBank accession numbers are summarized in [Table 2](#pone-0002079-t002){ref-type="table"}. Five of the 34 clones corresponded to genes previously reported as methylated in cancer. Four of the clones corresponded to bi-directional promoters. Chromosomal location of the clones appeared random with no evidence of clustering ([Table 2](#pone-0002079-t002){ref-type="table"}).

10.1371/journal.pone.0002079.t002

###### Hypermethylated promoter - associated CpG island clones isolated by MCA-RDA.

![](pone.0002079.t002){#pone-0002079-t002-2}

  No.           Gene name           Bidirectional    Locus     Location[\*](#nt103){ref-type="table-fn"}   Previously Reported \[reference\]
  ----- -------------------------- --------------- ---------- ------------------------------------------- -----------------------------------
  1                ALX3                  No          1p13.3              110324472--110324835                 Yes [@pone.0002079-Wimmer1]
  2               TFAP2E                 No          1p34.3               35708094--35708319                              No
  3               CLSTN1                 No         1p36.22                9818652--9818922                               No
  4         AW295421, BM809018           Yes         1q21.1              144745596--144745909                             No
  5               ETNK2                  No          1q32.1              200852162--200852445                             No
  6                NSE1                  No          2p24.3               14723003--14723236                              No
  7              AB029015                No          3p24.3               16900443--16900785                              No
  8              KIAA1729                No          4p16.1               10135303--10135580                              No
  9              BC048329                No          5q31.1              135556264--135556542                             No
  10               CDX1                  No           5q32               149526986--149527183                  Yes [@pone.0002079-Suh1]
  11         FLJ14166 (CCNJL)            No          5q33.3              159671339--159671601                             No
  12           NKX2-5 (CSX)              No          5q35.1              172593550--172593870                 Yes [@pone.0002079-Toyota1]
  13             AK128409                No          6p25.3                1565515--1565753                               No
  14              MOGAT3                 No          7q22.1              100632085--100632363                             No
  15               TOX                   No          8q12.1               60193205--60193432                              No
  16               DPYS                  No          8q22.3              105548353--105548518                             No
  17               SCXA                  No          8q24.3              145460987--145461257                             No
  18             BTBD14A                 No          9q34.3              136211905--136212286                             No
  19       SPOCK2 (Testican-2)           No         10q22.1               73517716--73517874                              No
  20             SLC16A12                No         10q23.31              91285295--91285471                              No
  21              FOXN4                  No         12q24.11             108209604--108209916                             No
  22     FLT1 (VEGFR-1), CR600638        Yes        13q12.3               27966278--27966465                  Yes [@pone.0002079-Yamada1]
  23          CDEP (FARP1 )              No         13q13.2               97592455--97592835                              No
  24               PAX9                  No         14q13.3               36202075--36202382                              No
  25         EGFR5 (C14orf27)            No         14q21.1               37794235--37794429                              No
  26          IRX5, AF275804             Yes        16q12.2               53523634--53523826                              No
  27              GALR2                  No         17q25.1               71581744--71581919                              No
  28         NFIC (AK129956)             No         19p13.3                3414086--3414270                               No
  29            LOC126147                No         19p13.33              53869474--53869704                              No
  30        BX537419, BQ068319           Yes        19q13.43              63550508--63550666                              No
  31               GCX1                  No         20q13.12              41978149--41978397                              No
  32              TFAP2C                 No         20q13.31              54634117--54634337                              No
  33              TIMP3                  No         22q12.3               31522005--31522204                 Yes [@pone.0002079-Cameron1]
  34              PP2447                 No         22q13.33              48925974--48926227                              No

Based on Blat ([www.genome.ucsc.edu](http://www.genome.ucsc.edu)) search of the May 2004 assembly.

COBRA and pyrosequencing analysis in Cell lines {#s3b}
-----------------------------------------------

To confirm the accuracy of MCA-RDA, differential methylation was investigated by COBRA analysis [@pone.0002079-Xiong1] or pyrosequencing for seventeen known genes (all except the 5 previouly known as methylated). All the MCA-RDA clones related to the genes analyzed in this study had CCCGGG sites on both sides consistent with the MCA technique. The primers for COBRA or pyrosequencing analysis were designed close to the promoter region in each case ([Figure 1](#pone-0002079-g001){ref-type="fig"}). [Figure 2](#pone-0002079-g002){ref-type="fig"} shows examples of the COBRA and pyrosequencing analysis. The PCR product was digested with restriction enzymes that distinguish methylated from unmethylated DNA after bisulfite treatment for COBRA assay ([Table 1](#pone-0002079-t001){ref-type="table"}). In order to determine the quantitative accuracy of the COBRA and pyrosequencing assays, we tested both assays on DNA from normal leukocytes, 2∶1 (33%) mixture, 1∶2 (67%) mixture and fully methylated DNA (100%) obtained by *Sss*I treatment. The assays showed significant correlations between predicted and measured values by pyrosequencing (GALR2, Pearson r  = 0.98, P\<0.001) and COBRA (SLC16A12, Pearson r = 0.99, P = 0.008; GALR2, Pearson r = 0.99, P = 0.002). We also compared data obtained by COBRA or pyrosequencing in 364 measurements, and found a high degree of correlation between the two methods (Pearson r = 0.939, n = 364 pairs, P\<0.001) ([Figure 2](#pone-0002079-g002){ref-type="fig"}). Similarly, correlations between two different pyrosequencing assays were very high (Pearson r = 0.977, n = 458 pairs, P\<0.001). All of the 17 genes investigated were methylated in at least 2 cell lines of a 21-cell line panel (summarized in [Figure 3A](#pone-0002079-g003){ref-type="fig"} and [Table S1](#pone.0002079.s001){ref-type="supplementary-material"}). Sixteen of the 17 analyzed genes showed hypermethylation in at least one of three prostate cancer cell lines. Only TFAP2C did not display hypermethylation in any prostate cancer cell line. For this gene, the MCA product was 2 Kb upstream of the promoter and COBRA showed methylation close to the MCA product (data not shown) but not in the gene promoter. Individual cell lines varied in methylation frequency from 5/17 (Hep3B) to 15/17 (RAJI) and colon cancer and leukemia appeared to have the most methylation. Seven out of 17 genes analyzed in this study had methylation in the non-tumorigenic urothelial epithelium SVHUC cell line, which was immortalized by SV40. However, the AD12-SV40-immortalized PWR-1E normal human prostate cell line [@pone.0002079-Webber1] did not show increased methylation of these genes (data not shown). Thus, acquired methylation in the SVHUC cell line could be derived from repeated passages and selection during cell culture.

![CpG island map and DNA methylation status of identified clones.\
CpG maps of the seventeen genes analyzed in this study. For each gene, short vertical bars indicate CpG sites. Exon1 is indicated by black rectangles at the top, whereas location of the MCA-RDA clones is indicated by red rectangles at the bottom. Arrows point to known or presumed transcription start sites. Blue bars at the bottom indicate areas that analyzed by COBRA or pyrosequencing.](pone.0002079.g001){#pone-0002079-g001}

![Representative COBRA and pyrosequencing for GALR2 and TFAP2C.\
For GALR2 and TFAP2C methylation analyses, we used COBRA (left panel) and pyrosequencing (right panel). The methylation density of pyrosequencing is presented in the top of each tracing as the averaged methylation of the CpG sites analyzed. Both methods analyzed almost the same sites in the promoter region as presented in [Figure 1](#pone-0002079-g001){ref-type="fig"}. A. In GALR2 methylation analysis, normal adjacent sample showed 9% methylation by COBRA and 6% by pyrosequencing but tumor sample showed 45% by COBRA and 42% by pyrosequencing. B. In TFAP2C methylation analysis, normal sample showed 1% methylation by COBRA and 3% methylation by pyrosequencing but tumor sample showed 61% by COBRA and 64% by pyrosequencing.](pone.0002079.g002){#pone-0002079-g002}

![Heat map of DNA methylation profiling of identified clones by MCA-RDA.\
The bottom red-scale bar refers to the degree of methylation as measured by COBRA and/or pyrosequencing. NL represents normal leukocyte. A. All of the 17 genes investigated were methylated in at least 2 cell lines of a 21-cell line panel investigated. B. Methylation map for 8 genes studied in twenty primary prostate cancers (T) and paired normal (N) prostate samples. C. Methylation map for 9 genes studied in twenty primary colon cancers (T) and paired normal (N) colon samples. D. Methylation map of 7 genes in twenty-four breast cancers (T) and paired normal (N) samples. Pat.; patient samples.](pone.0002079.g003){#pone-0002079-g003}

Analysis of Primary Prostate Cancer {#s3c}
-----------------------------------

Based on the CpG island methylation data from the 21-cell line panel, we selected 8 genes showing dense CpG island methylation in prostate cancer cell lines and further analyzed them in 20 primary prostate cancer and paired normal prostate samples. Compared to adjacent normal prostate, all 8 genes had significantly higher methylation in prostate cancer by t-test analysis (P\<0.001 for NKX2-5; P\<0.001 for SPOCK2; P = 0.004 for GALR2; P\<0.001 for CLSTN1; P\<0.001 for NSE1; P\<0.001 for DPYS; P = 0.019 for FOXN4; P\<0.001 for SLC16A12) ([Figure 3B](#pone-0002079-g003){ref-type="fig"}, [4A](#pone-0002079-g004){ref-type="fig"} and [Table S2](#pone.0002079.s002){ref-type="supplementary-material"}). FOXN4 and GALR2 were relatively rarely methylated while the other 6 genes showed remarkably increased methylation levels. Of note, NSE1 and DPYS also showed some degree of methylation in normal prostate (average 10±4% for NSE1 and average 24±9% for DPYS). The combination of DPYS or NSE1 hypermethylation showed a sensitivity of 80%, specificity of 95% and accuracy of 95% and the combination of NSE1 or SPOCK2 hypermethylation showed a sensitivity of 80%, specificity of 95% and accuracy of 96% in differentiating prostate cancer from normal ([Table 3](#pone-0002079-t003){ref-type="table"}).

![Scatter plots of methylation analysis in primary prostate cancer (A), colorectal cancer (B) and breast cancer (C).\
N and T represent tumor and adjacent normal. \*Significantly different from normal adjacent samples, *P*\<0.05.](pone.0002079.g004){#pone-0002079-g004}

10.1371/journal.pone.0002079.t003

###### Diagnostic information of single or combined candidate biomarkers isolated by MCA-RDA.

![](pone.0002079.t003){#pone-0002079-t003-3}

                              Biomarker        \% Sensitivity   \% Specificity   \% Accuracy
  ---------------------- -------------------- ---------------- ---------------- -------------
  ***Prostate Ca.***                                                            
                                NKX2-5               55               95             79
                               CALSTN1               65               95             92
                                SPOCK2               60               95             80
                                 NSE1                65               95             95
                               SLC16A12              55               95             90
                                FOXN4                40               95             69
                                GALR2                35               95             78
                                 DPYS                80               90             91
                            DPYS or NKX2-5           85               95             90
                           CALSTN1 or DYPS           75               95             94
                             NSE1 or DPYS            80               95             95
                            NSE1 or SPOCK2           80               95             96
                           SLC16A12 or DPYS          75               95             93
  ***Colorectal Ca.***                                                          
                                NKX2-5               70               95             71
                                SPOCK2               60               95             76
                                GALR2                85               95             98
                                FOXN4                35              100             70
                                TFAP2C               30               95             58
                                 DPYS                80               90             91
                               SLC16A12              85               95             91
                          NKX2-5 or SLC16A12         90               95             92
                          SPOCK2 or SLC16A12         90               95             94
                           GALR2 or NKX2-5           90               95             96
                           NKX2-5 or SPOCK2          80               95             89
  ***Breast Ca.***                                                              
                               SLC16A12              38               96             64
                                 DPYS                83               96             91
                                 TOX                 42               96             63
                                GALR2                67               88             87
                                SPOCK2               63               96             73
                                EGFR5                79               96             83
                             DPYS or TOX             88               96             91
                            A16 or SPOCK2            71               96             82
                             A16 or DPYS             63               96             90
                             EGFR5 or TOX            92               92             93

The other gene combinations did not improve the sensitivity markedly. The accuracy of a test is measured by the area under the Receiver Operating Characateristic (ROC) curve.

Analysis of Methylation in Other Cancers {#s3d}
----------------------------------------

Next, we studied colon cancer and breast cancer. The DNA hypermethylation status of 9 genes showing dense CpG island methylation in colon cancer cell lines was further analyzed in 24 primary colon cancer and paired normal colon samples. In a panel of 20 colon cancer cases, all these genes except IRX5, TFAP2E and TFAP2C showed significantly higher methylation in cancer by t-test analysis (P\<0.001 for NKX2-5, DPYS SPOCK2, GALR2 and SLC16A12; P = 0.008 for FOXN4) ([Figure 3C](#pone-0002079-g003){ref-type="fig"}, [4B](#pone-0002079-g004){ref-type="fig"} and [Table S3](#pone.0002079.s003){ref-type="supplementary-material"}). Notably, GALR2 and DPYS showed some degree of methylation in normal colon (average 8±4% for GALR2 and average 21±5% for DPYS). GALR2 hypermethylation showed a sensitivity of 85%, specificity of 95% and accuracy of 98% and the combination of GALR2 or NKX2-5 hypermethylation showed a sensitivity of 90%, specificity of 95% and accuracy of 96% for detecting colorectal cancer ([Table 3](#pone-0002079-t003){ref-type="table"}).

As shown in [Figure 3D](#pone-0002079-g003){ref-type="fig"}, the DNA hypermethylation status of 7 genes showing dense CpG island methylation in breast cancer cell lines was analyzed in 24 primary breast cancer and paired normal breast samples. Compared to adjacent normal breast, all 6 genes except NKX2-5 showed higher methylation in breast cancer by t-test analysis (P\<0.001 for DPYS and EGFR5 P = 0.01 for SLC16A12; P = 0.002 for TOX; P = 0.003 for GALR2) ([Figure 3B](#pone-0002079-g003){ref-type="fig"}, [4C](#pone-0002079-g004){ref-type="fig"} and [Table S4](#pone.0002079.s004){ref-type="supplementary-material"}). NKX2-5 was relatively rarely methylated while the other 6 genes showed remarkably increased methylation levels. Of note, EGFR5 showed some degree of methylation in normal breast (average 17±13%). The combination of EGFR5 or TOX hypermethylation showed a sensitivity of 92%, specificity of 92% and accuracy of 93% and the combination of DPYS or TOX hypermethylation showed a sensitivity of 88%, specificity of 96% and accuracy of 91% for detecting breast cancer ([Table 3](#pone-0002079-t003){ref-type="table"}).

Methylation and Gene Expression {#s3e}
-------------------------------

To confirm silencing by DNA methylation, we performed expression analysis by RT-PCR for eight genes, TFAP2C, NKX2-5, GALR2, DPYS, TFAP2E, CDEP, SPOCK2, and NSE1 selected based on methylation frequency and potential function ([Figure 5](#pone-0002079-g005){ref-type="fig"}). Most cell lines chosen for analysis had high methylation level (\>50%), and all had very low levels of expression at baseline. Expression of these genes was easily restored after treatment with the demethylating agent, 5-azadC in all cases suggesting silencing related to DNA methylation. The histone deacetylase inhibitor, TSA alone did not restore gene expression at TFAP2C, NKX2-5 and NSE1. The other genes showed increased expression after TSA but to a lesser extent than after 5-azadC treatment. For 5-azadC and TSA combined treatment, TFAP2C, TFAP2E, CDEP, SPOCK2 and NSE1 showed synergistic effects on expression.

![Silencing in cancer and reactivation of hypermethylation.\
Expression of target genes and GAPDH (control) was measured by RT-PCR in various cell lines. The sizes of the PCR products are listed in [Table 1](#pone-0002079-t001){ref-type="table"}. Most cell lines chosen for analysis had high methylation level (\>50%), and all had very low levels of expression at baseline, which was markedly increased by treatment with the methylation inhibitor, 5-azadC with or without the HDAC inhibitor TSA. Ctl.; no treatment, D; 5-AzadC alone, T; TSA alone, D+T; 5-AzadC and TSA in combination.](pone.0002079.g005){#pone-0002079-g005}

Discussion {#s3f}
----------

To isolate novel methylated genes in cancer, we applied MCA-RDA to prostate cancer cell lines and identified 34 promoter-associated CpG islands differently methylated compared to normal control. All of 17 genes investigated had hypermethylation in at least 2 cell lines of a 21-cell line panel containing prostate cancer, colon cancer, leukemia, and breast cancer. We thus confirmed that MCA-RDA is a very powerful tool to identify sequences methylated at multiple loci. MCA-RDA with repetitive subtractive hybridization is, however, labor intensive and costly, and requires hundreds of clones to be sequenced. A recent improvement was to couple MCA with microarrays [@pone.0002079-Estecio1] thus improving the yield of the method. MCA could also potentially be coupled with deep sequencing technology [@pone.0002079-Barski1].

In most of the cases, cancer cell lines exhibited higher levels of CpG island hypermethylation than primary cancers as previously shown [@pone.0002079-Smiraglia1]. For example, most prostate and colon cancer cell lines showed hypermethylation at FOXN4 and GALR2, but primary prostate cancers showed lower frequency methylation compared to primary colon cancer. Therefore, it seems likely that part of the hypermethylation events displayed in cancer cell lines come from repeated passages and adaptation to culture environment. In addition, compared to an immortalized cell line (PWR-1E) that was established in 1996, SVHUC cell line, established in 1987 [@pone.0002079-Christian1], showed increased methylation of some genes, likely derived from reiterated passages in cell culture. Nevertheless, our results also show that cancer cell lines maintain hypermethylation specificity because most methylation events in cancer cell lines also occur in some primary cancers.

DNA methylation provides a powerful diagnostic biomarker for cancer. It was recently estimated that hypermethylation is one order of magnitude more frequent than mutation in cancer [@pone.0002079-Schuebel1] DNA methylation could be useful for disease diagnosis in uncertain cancer, or for screening in body fluids [@pone.0002079-Laird1]. In this study, we identify high sensitivity markers for prostate cancer, colon cancer and breast cancer, which could be worth testing in appropriate surrogate samples (e.g. ejaculate, urine for prostate cancer; serum, stool for colon cancer; nipple aspirate for breast cancer etc.). It is also interesting that some of the genes show substantial methylation in 'adjacent' normal tissues. It remains to be seen whether this is related to age-dependent methylation [@pone.0002079-Issa1], [@pone.0002079-KwabiAddo1] or to a field defect specific to patients with cancer [@pone.0002079-Shen1]. It is also interesting to note tissue specific differences in methylation. For example, NKX2-5 is methylated in prostate and colon cancer, but rarely in breast cancer. GALR2 is hypermethylated in colon cancer and breast cancer but rarely in prostate cancer. The mechanisms underlying such differences deserve further investigation.

Our data identified TFAP2C and TFAP2E as potentially important new targets of transcriptional silencing in colon cancer. The AP-2 family of transcription factors consists of five homologous proteins, AP-2*α*, AP-2*β*, AP-2*γ*, AP-2*δ*, and AP-2*ε*. AP-2 transcription factors play important roles in embryonic development by influencing the differentiation, proliferation, and survival of cells. The overexpression of AP-2 in HepG2 human hepatoblastoma and SW480 human colon adenocarcinoma cells inhibited cell division and colony formation [@pone.0002079-Zeng1]. Importantly, re-expression of AP-2 in AP-2 negative melanoma cells suppressed their tumorigenicity and metastatic potential in nude mice [@pone.0002079-Huang1]. These data suggest that AP-2 transcription factors are involved in the maintenance of a proliferative and undifferentiated state of cells, a characteristic not only important to embryonic development but also to tumorigenesis.

Some of the other genes identified could also be functionally important. However, the methylation observed here may also simply reflect the global redistribution of 5-methylcytosine during cancer development [@pone.0002079-Schmutte1]. Thus, these clones should be functionally investigated before conclusions can be made regarding their role in cancer. In conclusion, our data identify potentially important new targets of transcriptional silencing in cancer, and provide new biomarkers that could be useful in screening for prostate cancer, colon cancer and breast cancer.
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